Sandeep Laumas

Prior to joining Instil Bio, Dr. Laumas has been actively involved in healthcare investing and serving on company Boards of Directors. Dr. Laumas began his career at Goldman Sachs & Co. in 1996 as an equity analyst in the healthcare investment banking division working on mergers, acquisitions and corporate finance transactions before transitioning to the healthcare equity research division. After leaving Goldman Sachs in 2000, Dr. Laumas moved to the buy side as an analyst at Balyasny Asset Management from 2001 to 2003. Dr. Laumas was a Managing Director of North Sound Capital from 2003 to 2007 (global healthcare investments). Since 2007, he has been investing in healthcare via investment vehicles, Bearing Circle Capital, and serving on the Boards of Directors including Bioxcel Therapeutics, Inc. (Nasdaq: BTAI) (2017-present), executive chairman and currently a member of the Board of Directors of 9 Meters Biopharma, Inc. (Nasdaq: NMTR) (2014-present), Parkway Holdings Ltd. (acquired by IHH Healthcare for $3 Billion) (2010) and SRL Laboratories Ltd. (2011). Dr. Laumas received his A.B. in Chemistry from Cornell University in 1990, M.D. from Albany Medical College in 1995 with a research year at the Dana-Farber Cancer Institute and medical internship in 1996 from the Yale University School of Medicine.